InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,808.12
(
-0.03%
)
US TECH 100
19,984.80
(
0.87%
)
Dow Jones
42,114.40
(
-0.61%
)
Brent Oil
71.09
(
-2.16%
)
Bitcoin
68,531.90
(
0.90%
)
Post# of 58465
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

nutriman24

Send PM Follow Ignore
Followers 25
Posts 4535
Boards Moderated 0
Alias Born 07/08/2008

nutriman24

Re: Dante64 post# 20082

Thursday, 04/23/2009 11:06:53 AM

Thursday, April 23, 2009 11:06:53 AM

Post# of 58465
Brd. 2 Pharmacology and safety factors affecting
use of flat (rather than
weight-based) dosing of tesetaxel, an
orally administered taxane. (Abstract
#2510)
R. P. Warrell, M. Beeram, E. Spindler, K.
Papadopoulos, A. Patnaik, A. W. Tolcher

Page 281.....http://www.asco.org/ASCO/Downloads/Meetings%20Services/2009%20Annual%20Meeting/Program%20by%20Day.pdf


Page 239

Brd. H3 Survival of advanced melanoma patients
with normal LDH treated with
oblimersen, temozolomide, and nabpaclitaxel.
(Abstract #9080)
A. C. Pavlick, P. Ott, J. Escalon, K.
Madden, E. Yepes, J. Staha, S. Mendoza,
A. Gandhi, H. Yee, L. Liebes



Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up